FAIRFIELD, Conn., Aug. 10, 2007 (PRIME NEWSWIRE) -- Competitive Technologies, Inc. (AMEX:CTT) announced that John B. Nano, CTT's Chairman, President and CEO, in an interview yesterday discussed CTT's recently acquired exclusive worldwide distribution rights to a pain management therapy for treating oncological and neuropathic pain. The non-invasive treatment has already been used with successful results in seven hospitals in Italy on over 200 patients suffering from intense drug-resistant pain. This treatment uses a multi-processor device able to simultaneously treat multiple pain areas by applying surface electrodes to the skin.
The innovative technology is from the research of Professor Giuseppe Marineo of Delta Research & Development in Rome. CTT was able to successfully and quickly complete the agreement with the Italian company with assistance from the Zangani Investment Community(tm).
Also discussed in the interview was the technology for stress reduction, improved concentration and age-related memory improvement. The Korean device called MC Square uses synchronized sound and light rhythms to influence brain activity. Over 1.2 million units of the pocket-sized device have been sold in the Korean market. The MC Square targets market segments from students to the aging population. The patent-pending technology licensed to CTT for U.S. distribution was developed by Thomas Jefferson University in Philadelphia and Korea-based Daeyang E&C, Inc. (KOSDAQ:033030).
Mr. Nano noted that CTT is actively pursuing additional technologies, especially in the life science and alternative energy fields, and that there are additional technology agreements that CTT is pursuing in the Italian market, as well as other countries. The complete interview may be heard at (http://www.zangani.com/webcasts/20070809/ctt).
"We will continue our interest in obtaining technologies that fulfill consumer needs," said Mr. Nano. "We are aggressively marketing our newly acquired pain management technology and stress reduction technology, as well as our other technologies, including our HB LEDs, bone biomaterial, cholesterol trapping and regeneration, and Lupus diagnostic and monitoring, to drive revenue growth, improve profitability and create shareholder value."
About Competitive Technologies, Inc.
Competitive Technologies, established in 1968, is a full service technology transfer and licensing provider focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website: www.competitivetech.net
Statements about our future expectations are "forward-looking statements" within the meaning of applicable Federal Securities Laws, and are not guarantees of future performance. When used herein, the words "may," "will," "should," "anticipate," "believe," "appear," "intend," "plan," "expect," "estimate," "approximate," and similar expressions are intended to identify such forward-looking statements. These statements involve risks and uncertainties inherent in our business, including those set forth in Item 1A under the caption "Risk Factors," in our most recent Annual Report on Form 10-K for the year ended July 31, 2006, filed with the SEC on October 30, 2006, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.